Microbial strains and methods for the antibiotic-free fermentation preparation of low molecular weight substances and proteins

By introducing non-compensating auxotrophic gene mutations into microbial strains and using temperature-sensitive plasmids, the cost and risk issues associated with antibiotic selection markers were resolved, and the stability and yield of plasmids in composite culture media were improved.

CN113755417BActive Publication Date: 2024-11-12WACKER CHEMIE AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110598800.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2015-12-11
Publication Date
2024-11-12
Estimated Expiration
2035-12-11

AI Technical Summary

Technical Problem

In existing technologies, using antibiotics as selection markers in the production of low molecular weight substances and proteins by microbial fermentation is costly and carries the risk of resistance gene diffusion. It is also difficult to maintain the stability of plasmids in complex culture media, resulting in unsatisfactory yields.

Method used

By introducing unsupplemented auxotrophic gene mutations into the genome of microbial strains and replacing the production plasmids into cells using temperature-sensitive plasmids, the stability of the plasmids in composite culture media is ensured, avoiding the use of antibiotics.

Benefits of technology

This method enables the stable existence of plasmids in composite culture media, improves the production efficiency of low molecular weight substances and proteins, reduces production costs, and reduces the risk of resistance gene spread.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113755417B_ABST
    Figure CN113755417B_ABST
Patent Text Reader

Abstract

The present invention relates to microbial strains and methods for preparing low molecular weight substances and proteins by bio-antibiotic fermentation. The microbial strain used to produce low molecular weight substances or proteins contains a mutation in a gene in its genome, which causes nutritional deficiency in the strain. It further contains a production plasmid encoding an enzyme or recombinant protein and a functional copy of a gene, wherein the enzyme is used to produce the low molecular weight substance, the chromosomal inactivation of the gene causes nutritional deficiency, wherein the nutritional deficiency is an irreparable nutritional deficiency.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of Chinese patent application No. 201580085273.3, entitled “Microbial strains and methods for preparing low molecular weight substances and proteins by antibiotic-free fermentation”, filed on June 11, 2018.

[0002] The present invention relates to a microbial strain and a method for producing low molecular weight substances and proteins by fermentation without antibiotics.

[0003] First and foremost, the natural production of low molecular weight substances by means of microorganisms has increased, and the market of recombinant protein drugs ("biological preparations") has also shown strong growth in recent years. Due to the high cost pressure in fermentation production (especially for protein-based active pharmaceutical ingredients), more effective and therefore more cost-effective methods and systems for its production are being sought. Various microorganisms, such as bacteria, yeast, filamentous fungi or other plant cells or animal cells can be used as producers. Here, it is crucial from an economic point of view to obtain the correct folding and / or modification of functional proteins in the case of proteins in economically efficient fermentation, high product yields. Due to its extensively studied genetics and physiology, short passage time and simple handling, Gram-negative enterobacteriaceae Escherichia coli (Escherichia coli, E. coli) is the organism most commonly used to produce low molecular weight substances and proteins.

[0004] Basically, two different microorganisms are used: microorganisms that naturally produce the substances and microorganisms that have been genetically modified. The technical methods required for genetic modification have long been known in the prior art. The goal here is to introduce the genes required for the target protein or for the synthesis of low molecular weight substances into the host cell. The genes are transcribed by the host cell, translated, modified if necessary, and possibly transferred outwardly into the culture medium.

[0005] The economic feasibility of a biotechnological process depends crucially on the yield of the product obtained. The yield can be optimized via the expression system (host cells, genetic elements, etc.), fermentation parameters and culture medium.

[0006] Basically, host cells can be modified in two different ways.Thereby, new genetic information can be integrated into genome (filamentous fungi, yeast etc.) and / or imported into (for example plasmid) on extrachromosomal element (prokaryotes, yeast etc.).In the situation that gene inheritance is integrated into genome, even without selection pressure, described gene is still well kept in host cell.But the shortcoming is that in prokaryotes situation, only one gene copy is present in host, and due to sequence-specific recombination event, further copy of the same gene is integrated, and it is very challenging (EP 0284126 B1) to increase product formation by gene-dosage effect.

[0007] When using extrachromosomal DNA, the genetic information of the target protein in the form of a plasmid is usually transformed into the E. coli production strain. Since the gene-dosage effect also works here, the highest possible number of plasmid copies per cell is sought. Since this genetic factor is easily lost from the cell due to stress (due to the replication of the plasmid and the production of the target protein), it is necessary to apply selection pressure to the entire culture. It is standard to use an antibiotic resistance gene as a selection marker, which allows cells containing this element to grow in the presence of antibiotics. Therefore, only cells carrying plasmids can reproduce. Since the ability to produce the target substance or target protein is also lost due to plasmid loss, this has a direct impact on the yield that can be achieved in fermentation.

[0008] In recent years, the use of antibiotic resistance as a selection marker has received increasing attention. First, the use of antibiotics is quite expensive, especially when the resistance is based on antibiotic-degrading enzymes, because additional doses of antibiotics need to be continuously provided. Secondly, the widespread use in medicine and other fields has contributed to the spread of resistance genes to other strains, in some cases pathogenic strains. This has a negative impact on the treatment of diseases.

[0009] Meanwhile, antibiotic-free selection systems have also been developed in the prior art. A variety of different antibiotic-free systems have been developed. These can be divided into three different basic systems. Using auxotrophy, toxin-antitoxin systems and other methods.

[0010] The category of other methods covers mechanisms that do not follow general principles, such as inhibitor tRNA, fab I / triclosan (FA synthesis), operator / repressor titration (Peubez et al.Microbial Cell Fac, 2010, 9:65). However, these methods are generally used to synthesize DNA and DNA fragments for gene therapy and are not optimized for producing high-yield target substances. In some cases, other substances such as triclosan, herbicides and heavy metals are used instead of antibiotics for selection, but they can also cause health problems. For example, Herrero et al. (1990, J.Bacteriol.172, 6557-6567) describes herbicide and heavy metal resistance genes as selection markers.

[0011] The toxin-antitoxin system (Hok-Sok, ccdA / B, etc.) consists of two genetic elements, which may be encoded on the plasmid or encoded on the chromosome and the plasmid (Gerdes et al. Proc Natl Acad Sci USA, 1986, 83: 3116–20). Here, the antitoxin has a neutralizing effect on the toxin. In the case of plasmid loss, this mechanism is lost and the cell dies due to the chromosomally encoded and long-lasting toxin without plasmids.

[0012] Another known selection method is the complementation of auxotrophic strains. Here, genes with basic metabolic functions in the production strain genome are removed or inactivated. Therefore, these genes are called essential genes. Only when metabolic functions are circumvented or re-established, the resulting auxotrophic strains can grow, reproduce or survive. This can be achieved by giving appropriate precursors or metabolic terminal products (amino acids, bases, etc.) or by importing genes inactivated in the host genome. Patent EP 0284126 B1 has named auxotrophic markers for amino acid metabolism. Since auxotrophy can be easily supplemented by adding essential metabolites in the culture medium, these strains can be easily produced. This is because cells can be cultured under the conditions of metabolites even in the absence of plasmids. By conversion, the synthetic information of amino acids / bases is re-introduced into the cells, and cells can also grow even in the absence of supplementation conditions. Therefore, selection must be completed on the minimal medium without supplementation.

[0013] In fact, owing to the substratum with composite composition being generally used for industrial fermentation, therefore also can not implement and use this auxotrophy as selective marker so far.At this, for cost reason, waste product is the component of fermentation medium normally, for example the residue of cereal (ethanol production), corn (starch production), potato (starch recovery) or yeast extract.These are used as carbon source and nitrogen source.In some cases, these components are not accurately defined, but contain amino acid, base, vitamin etc., which can be taken in from substratum.Therefore, if possible, also be difficult to set up enough selection pressure with auxotrophic strain in industrial fermentation.

[0014] As described in WO2008 / 135113A1, in glucose metabolism, using auxotrophy in the culture medium in industrial applications also has insufficient selectivity. Although microorganisms can grow particularly well on glucose and breed faster than culture medium containing other carbon sources, this advantage is negated due to higher stress caused by the generation of plasmid or target substance. Other carbon sources can be used for composite culture medium and are used for cells.

[0015] This also applies to the use of the pyrC gene (dihydroorotase) as an auxotrophic marker, as described in WO07039632A1. This enzyme is present at the start of pyrimidine base synthesis, and inactivation also leads to inhibition of resynthesis. However, these bases can be obtained from the culture medium and utilized, and appropriate selection pressure cannot be established in industrial culture media.

[0016] The exceptions are the auxotrophy for the essential thymidine and D-alanine, which are present only in trace amounts or not at all in the fermentation medium even in the complex composition (EP 0251579 A1; EP 0185512 B1). However, these systems are also not suitable for efficient production in the high cell density processes usually sought. Because some cells die and lyse in the process, thymidine and D-alanine or other amino acids are released, which can in turn fill the auxotrophy.

[0017] In general, it must be pointed out that despite many years of experience in the fermentative production of low molecular weight substances and proteins, no generally usable systems have been developed so far, except by substances such as antibiotics which are expensive or represent a health and / or environmental risk. Due to the complex growth media used in industry, various methods for selection by auxotrophic markers have also so far only brought unsatisfactory results.

[0018] This applies primarily to microorganisms, but especially to less robust production strains, such as leaky strains which are used due to their special properties (release of proteins into the medium). In the case of industrial use of such strains on an industrial scale, such use usually uses complex components in the medium.

[0019] For the production of industrially used products, it is uneconomical to use defined media consisting of purified components for cost reasons.

[0020] An object of the present invention is to provide a microbial strain for producing low molecular weight substances or proteins, which strain remains stable even in a culture medium containing complex components and in which a production plasmid is not stabilized in the cell by an antibiotic / resistance marker system.

[0021] This object is achieved by a microbial strain containing a genetic mutation in its genome, which mutation causes an auxotrophy in the strain, and which also contains a production plasmid encoding at least one enzyme for the production of low molecular weight substances or at least one recombinant protein, and a functional copy of a gene, the chromosomal inactivation of which leads to the auxotrophy, characterized in that the auxotrophy is an irreparable auxotrophy.

[0022] In the context of the present invention, an uncomplementable auxotrophic deficiency is understood to mean that the auxotrophic deficiency reduces the growth of the microbial cells or leads to the death of the microbial cells and cannot be complemented by adding metabolically specific precursors, intermediates and / or end products to the growth medium.

[0023] In the context of the present invention, there is reduced growth when the growth rate of the strain in fermentation after the gene mutation is reduced to ≤ 10% compared to the growth rate of the strain before the gene mutation, preferably when there is no more growth.

[0024] Particularly preferably, the mutation leads to the inactivation of a gene, in this way resulting in an irreparable auxotrophic deficiency and thus to the death of the microbial cell.

[0025] Thus, in the genome of the cells of the microbial strains according to the invention, genes important for anabolic pathways essential for cell growth or survival are inactivated, and it is no longer possible to achieve cell growth or survival by adding metabolically specific precursors, intermediates and / or end products to the growth medium.

[0026] A non-complementable auxotrophic gene in the context of the present invention is a gene in the genome of a microbial cell, the inactivation of which cannot be complemented by the addition of metabolic specific precursors, intermediates and / or end products to the growth medium, and the inactivation of which results in a reduction in the growth rate or death of the microbial cell.

[0027] Preferably, the mutation in a gene which results in a non-complementable auxotrophy in the strain results in the inactivation of said gene or inactivation of the activity of the gene product encoded by the gene.

[0028] Examples of non-complementable auxotrophic genes (lethal genes) are described in Baba et al. (2006, Mol. Syst. Biol. 2: 2006.0008). Preferably, the gene is the gene map, pyrH, ftsL, rpsB, tsf, plsC or a homologous gene thereof.

[0029] Particularly preferably, the gene is the pyrH gene or the plsC gene or a homologous gene having the same function or activity.

[0030] A gene in the context of the present invention comprises not only the DNA segment which is transcribed, but also the DNA segment which is involved in regulating this replication process, ie the regulatory elements of the gene, such as preferably a promoter and a terminator.

[0031] Homologous genes are preferably understood to mean genes which encode proteins having the same activity as the protein encoded by the specified gene and which have a sequence identity of more than 30%, particularly preferably more than 70%, with the sequence of the specified gene in the microorganism under consideration, which sequence is in each case known from the databases.

[0032] The pyrH gene encodes the enzyme UMP kinase (EC: 2.7.4.22; UK, uridine monophosphate kinase, uridylate kinase, uridine 5'-monophosphate (UMP) kinase). The enzyme uses ATP to activate UMP to form UDP. In the next step, UDP is activated by another kinase (UDP kinase) to form UTP, which can be used to synthesize RNA as well as to synthesize CTP (cytosine triphosphate) and TTP (thymine triphosphate). CTP and TTP, in turn, are components of RNA (CTP) and DNA (dCTP and dTTP). Therefore, UMP is the origin of the pyrimidine building blocks of RNA and DNA. Since the conversion of uracil to cytosine or thymine occurs only at the triphosphate level, the inactivation of UMP kinase leads to a complete blockage of this synthetic pathway.

[0033] Basically, cells can only take up the monophosphates of the three bases from the culture medium. UMP kinase is essential for the conversion of UMP to UTP. This means that this auxotrophic deficiency cannot be compensated by supplementation and is therefore independent of the culture medium components.

[0034] The pyrH gene is characterized by SEQ ID No. 1. The pyrH gene product (PyrH) is characterized by SEQ ID No.2.

[0035] In the present invention, a pyrH homologue is a gene encoding a protein having PyrH activity and having a sequence identity of more than 30% with SEQ ID No. 1. Particularly preferably, it has a sequence identity of more than 70% with SEQ ID No. 1. The pyrH gene is particularly preferred.

[0036] A PyrH homologue is a protein having a sequence identity of greater than 30% with SEQ ID No. 2, which protein has UMP kinase activity according to EC number 2.7.4.22. Particularly preferably, a PyrH homologue has UMP kinase activity according to EC number 2.7.4.22 and a sequence identity of greater than 70% with SEQ ID No. 2. PyrH proteins are particularly preferred.

[0037] PyrH activity in cells can be determined according to the assay described by Bucurenci et al. (1998, J. Bact. 180:473-77).

[0038] The plsC gene encodes the enzyme 1-acylglycerol-3-phosphate O-acyltransferase (EC: 2.3.1.51). The enzyme transfers a fatty acid from acyl-CoA to an acylglycerol-3-phosphate and releases a CoA-SH. The resulting diacylglycerol 3-phosphate is used to synthesize necessary membrane components such as triglycerides and glycerophospholipids. This means that this step is essential for the production of the E. coli membrane system. In E. coli, although fatty acids can be taken up, triglycerides and glycerophospholipids must be synthesized in the cell or membrane.

[0039] The plsC gene is characterized by SEQ ID No. 3. The plsC gene product (PlsC) is characterized by SEQ ID No.4.

[0040] In the present invention, a plsC homolog is a gene encoding a protein having PlsC activity and having a sequence identity of more than 30% with SEQ ID No. 3. Particularly preferably, it has a sequence identity of more than 70% with SEQ ID No. 3. The plsC gene is particularly preferred.

[0041] A PlsC homologue is a protein having a sequence identity of greater than 30% with SEQ ID No. 4, which protein has 1-acylglycerol-3-phosphate O-acyltransferase activity according to EC number 2.3.1.51. Particularly preferably, a PlsC homologue has 1-acylglycerol-3-phosphate O-acyltransferase activity according to EC number 2.3.1.51 and has a sequence identity of greater than 70% with SEQ ID No. 4. PlsC proteins are particularly preferred.

[0042] PlsC activity in cells can be determined according to the assay described by Monrand et al. (1998, Biochem. Biophys. Res. Commun. 244:79-84).

[0043] The degree of DNA identity is determined by the program "nucleotide blast", which can be found on the web page http: / / blast.ncbi.nlm.nih.gov / and is based on the blastn algorithm. The default parameters are used as algorithm parameters for the comparison of two or more nucleotide sequences. The default general parameters are: Max target sequences = 100; Shortqueries = "Automatically adjust parameters for short input sequences"; ExpectThreshold = 10; Word size = 28; Automatically adjust parameters for short inputsequences = 0. The corresponding default scoring parameters are: Match / Mismatch Scores = 1, -2; Gap Costs = Linear.

[0044] For protein sequence comparison, the program "protein blast" from the web page http: / / blast.ncbi.nlm.nih.gov / was used. The program is based on the blastp algorithm. The default parameters were used as algorithm parameters for the comparison of two or more protein sequences. The default general parameters are: Max target sequences = 100; Short queries = "Automatically adjust parameters for short input sequences"; Expect Threshold = 10; Word size = 3; Automatically adjust parameters for short input sequences = 0. The default scoring parameters are: Matrix = BLOSUM62; Gap Costs = Existence: 11 Extension: 1; Compositional adjustments = Conditional compositional score matrix adjustment.

[0045] In order to produce bacterial strain of the present invention, the temperature-sensitive plasmid with the functional copy of the auxotrophic gene that can not be supplemented of sudden change or disappearance is imported into the suitable microorganism strain. Subsequently, the corresponding auxotrophic gene that can not be supplemented in the described bacterial strain genome of inactivation. Afterwards, the temperature-sensitive plasmid is changed into a production plasmid in the described bacterial strain under non-permissive temperature, wherein the production plasmid of at least one enzyme that encodes and is used to produce low-molecular-weight substances or at least one recombinant protein also contains the functional copy of the auxotrophic gene that can not be supplemented.

[0046] This method ensures that even in complex culture medium, the production plasmid is stably maintained in the cell during the fermentation process of producing low molecular weight compounds or recombinant proteins. Therefore, the strain according to the present invention can be cultivated without losing the plasmid in the absence of an added selective agent or an additive to supplement auxotrophic deficiency.

[0047] Basically, any microbial strain having a gene, the inactivation of which leads to an irreparable auxotrophic deficiency of the strain is suitable as starting strain for producing the strains according to the invention.

[0048] Preferably, the starting strain used to produce the strain of the present invention is a strain of the family Enterobacteriaceae, particularly preferably a strain of the species Escherichia coli.

[0049] Preferred E. coli strains are those with "leaky" mutations. "Leaky mutations" are understood to refer to mutations in genes of structural elements of the outer cell membrane or cell wall, selected from the group consisting of omp genes, tol genes, excD genes, excC genes, lpp genes, pal genes, env genes and lky genes, which mutations cause cells to release periplasmic proteins into the culture medium to an increased degree (Shokri et al., Appl. Microbiol. Biotechnol. 60 (2003), 654-664). Preferably, "leaky" mutations are mutations in the lpp gene, particularly preferably selected from the group consisting of lpp1 mutations, lpp deletion mutations and Lpp protein 14 glycine residue mutations (numbering system includes signal peptides), for example, lpp-3 mutations. The lpp1 mutation is a mutation in the lpp gene that causes the arginine residue at position 77 to be replaced by a cysteine ​​residue, and the lpp3 mutation is a mutation in the lpp gene that causes the glycine residue at position 14 to be replaced by an aspartic acid residue. These mutations are described in detail in US2008254511. The lpp deletion mutation is preferably a deletion of at least one nucleotide in the lpp gene itself or in the promoter region of the lpp gene, resulting in cells exhibiting increased periplasmic protein leakage.

[0050] In the context of the present invention, increased leakage is understood to mean that after fermentation of the cells the concentration of periplasmic proteins, such as alkaline phosphatase, in the culture medium is higher than in the culture medium of E. coli strain W3110 (ATCC 27325) fermented under the same conditions.

[0051] Methods for inactivating genes in microbial strains are known in the prior art. The mutations of two preferred genes (pyrH gene and plsC gene) and their gene products are described in detail below. These methods can also be applied in a similar manner to other genes whose inactivation causes the non-complementary auxotrophic deficiency of microbial strains.

[0052] The temperature-sensitive plasmid contains a temperature-sensitive replication origin and a functional copy of an irreparable auxotrophic gene. In addition, the plasmid contains a selection marker gene for selecting a transformant. The selection marker is, for example, antibiotic resistance.

[0053] A preferred example of a temperature-sensitive origin of replication is "oriR101&repA101-ts", a derivative of the origin of replication of plasmid pSC101 (Hashimoto-Gotoh et al.; Gene, 2000, 241:1:185-191), which is located, inter alia, on plasmids pKD20 and pKD46 (Datsenko and Wanner, 2000, PNAS 97:6640-6645).

[0054] The temperature-sensitive plasmid is introduced into cells using a transformation technique known to those skilled in the art, such as the TSS method, the CaCl / RbCl method, or the electroporation method.

[0055] Cells containing the temperature sensitive plasmid are selected by the selectable marker present on the temperature sensitive plasmid and the cells are incubated at a temperature that is permissive for the plasmid.

[0056] By culturing the microbial strain after transformation with the production plasmid at a temperature non-permissive for the temperature-sensitive plasmid, the temperature-sensitive plasmid can be replaced by the production plasmid. The preferred non-permissive temperature range is 37-45°C, particularly preferably 39-43°C.

[0057] The production plasmid is introduced into the cells using transformation techniques known to those skilled in the art, such as the TSS method, the CaCl / RbCl method, the electroporation method.

[0058] The transformant can be cultured on agar plates and in liquid culture. In a preferred embodiment, the microbial strain is exposed to a temperature shock of 47-55°C, preferably 52°C, for 30-90 minutes, preferably 60 minutes, immediately after transformation with the production plasmid. It is then further incubated at a non-permissive temperature. As a result, the temperature-sensitive plasmid replaces the production plasmid in one step, and the production strain of the present invention for antibiotic-free production of low molecular weight substances or recombinant proteins is produced.

[0059] For example, one of the following known expression vectors is used as a production plasmid: pJF118EH, pKK223-3, pUC18, pBR322, pACYC184, pASK-IBA3 or pET.

[0060] In addition to the functional copy of the auxotrophic gene that cannot be supplemented, the production plasmid also comprises one or more target genes and the necessary expression signals for expressing the target genes, such as promoter sequences, operator sequences and terminator sequences. The target gene encodes at least one enzyme or at least one recombinant protein for producing low molecular weight substances. Low molecular weight substances are basic structural modules (bases, amino acids, fatty acids, etc.) and secondary metabolites (vitamins, antioxidants, etc.) that organisms can synthesize. Preferably, amino acids, particularly preferably amino acid L-cysteine ​​and compounds derived therefrom.

[0061] The recombinant protein is preferably a heterologous protein.

[0062] A heterologous protein is understood to mean a protein which does not belong to the proteome, ie the overall natural protein composition, of the host organism.

[0063] Preferably, the heterologous protein is a eukaryotic protein, particularly preferably a protein that contains one or more disulfide bonds or exists in its functional form as a dimer or multimer, i.e. the protein has a quaternary structure and is built up of a plurality of identical (homologous) or different (heterologous) subunits.

[0064] A preferred class of proteins composed of multiple protein subunits is an antibody or an antibody fragment. Functional Fab antibody fragments are particularly preferred.

[0065] The following describes the production of a microbial strain according to the invention in which the non-complementable auxotrophic gene pyrH has been mutated.

[0066] Basically, any host organism which has the gene for the UMP kinase PyrH is suitable as a starting strain for producing a microbial strain according to the invention having a genomic pyrH inactivation.

[0067] Methods for inactivating the pyrH gene in a microbial strain are known in the prior art. For example, the pyrH gene can be inactivated by introducing a mutation (substitution, insertion or deletion of one or more nucleotides) in the reading frame of the pyrH gene, which mutation results in the inactivation of the specific activity of PyrH. Methods for producing such pyrH alleles are known to those skilled in the art. For example, chromosomal mutations can be inserted into the gene by homologous recombination mechanisms by the method described by Link et al. (1997, J. Bacteriol. 179: 6228–37). For example, chromosomal deletions of all or part of the pyrH gene can be performed by means of the lambda red recombinase system according to the method described by Datsenko and Wanner (2000, Proc. Natl. Acad. Sci. USA. 97: 6640–5). The pyrH allele can also be transferred to a pyrH wild-type strain by P1 phage transduction or conjugation with a strain having a pyrH mutation, and the pyrH wild-type gene in the chromosome is replaced by the corresponding pyrH allele.

[0068] In addition, the pyrH gene of the cell can also be inactivated by mutation of at least one element necessary for regulating expression (e.g. promoter, enhancer, ribosome binding site) by substitution, insertion or deletion of one or more nucleotides. In the context of the present invention, inactivation occurs when the growth rate of the fermentation cell is reduced to ≤10% due to gene inactivation compared to the cell before mutation, preferably no longer growing.

[0069] It is particularly preferred that the mutation results in cell death of the microorganism.

[0070] Since inactivation of the pyrH gene results in an irreparable auxotrophic deficiency, a functional copy of the pyrH gene must already be present in the cell prior to chromosomal inactivation. This can be achieved by transiently introducing a temperature-sensitive plasmid containing a functional copy of the pyrH gene.

[0071] In such cells containing a temperature-sensitive plasmid, the pyrH gene in the genome can be inactivated by the method described.

[0072] In a further step, the temperature-sensitive plasmid is exchanged for a production plasmid, which also contains a functional copy of the pyrH gene. This is preferably done in the manner already described.

[0073] Microbial strains of the invention having an inactivated plsC gene or some other mutated non-complementable auxotrophic gene can be generated in a similar manner.

[0074] In the production of recombinant proteins, a distinction is made between cytoplasmic production and secretory production. In the case of cytoplasmic production, the target protein accumulates in the cytoplasm of the cell, whereas in the case of secretory production, the target protein is transferred to the periplasm or culture medium. Secretory production is preferred in the context of the present invention. Particularly preferred is secretory production of the target protein into the culture medium.

[0075] In order to produce protein secretion, i.e., protein is transferred from the cytoplasm to the periplasm or culture medium, it is necessary to connect the 5' end of the protein gene produced in accordance with the reading frame to the 3' end of the signal sequence so that the protein is exported. It is mainly suitable for this purpose to cause the target protein to be transferred to the genes of all signal sequences in the periplasm in Escherichia coli. In Escherichia coli, three major transfer pathways are known: SEC pathway, TAT pathway and SRP pathway. Preferred signal sequences are those that allow translocation by the SEC device. The prior art describes each signal sequence of this type, such as the signal sequence of the following genes: phoA, ompA, pelB, ompF, ompT, lamB, malE, dsbA, staphylococcal protein A, StII etc. (Choi and Lee, Appl.Microbiol.Biotechnol.64 (2004), 625–635).

[0076] Preferred according to the present invention is the signal sequence of the phoA gene or ompA gene of Escherichia coli, or the signal sequence of cyclodextrin glycosyltransferase (CGTase) of Klebsiella pneumoniae M5a1, or a sequence derived from this signal sequence, which is disclosed in US2008076157.

[0077] The cultivation (fermentation) of cells containing the production plasmid is carried out according to conventional fermentation methods known to those skilled in the art in a bioreactor (fermenter) without the addition of antibiotics.

[0078] The present invention also provides a method for producing a low molecular weight substance or a recombinant protein by a microbial strain, the method being characterized by using the microbial strain according to the present invention and using a fermentation medium free of antibiotics.

[0079] The fermentation is carried out in conventional bioreactors, such as stirred tanks, bubble cap fermenters or airlift fermenters. Stirred tank fermenters are preferred on an industrial scale, thus having a size >100 L.

[0080] In fermentation, the cells of the strain of the present invention are cultured in a liquid medium, and various parameters such as the supply of nutrients, oxygen partial pressure, pH and culture temperature are continuously monitored and precisely controlled. The culture period is preferably 16-150 hours, particularly preferably 24-72 hours.

[0081] Possible fermentation media are all common media known to the person skilled in the art for culturing microorganisms. However, the fermentation medium does not contain any antibiotics.

[0082] Complex media or minimal salt media can be used, to which complex components such as peptone, tryptone, yeast extract, molasses or corn steep liquor are added in defined proportions. Media containing complex media components are preferred.

[0083] As the main carbon source of fermentation, sugar, sugar alcohol or organic acid or its salt available to all cells can be used. Preferably glucose, lactose or glycerol are used. Glucose and lactose are particularly preferred. A variety of different carbon sources can also be given in combination. The carbon source can be initially charged into the fermentation medium at the beginning of the fermentation, or initially nothing is added or only part of the carbon source is first added at the beginning, and the carbon source is added during the whole fermentation process. A particularly preferred embodiment is to initially add part of the carbon source and supplement part. Particularly preferably, the carbon source is initially added at a concentration of 10-30g / l, and supplementation is started when the concentration drops to less than 5g / l, thereby maintaining a concentration less than 5g / l.

[0084] The partial pressure of oxygen (pO2) in the culture is preferably between 10 and 70% saturation. A pO2 of 20 to 60% is preferred; a pO2 between 45 and 55% saturation is particularly preferred.

[0085] The culture pH is preferably between pH 6 and pH 8. The preferred pH is between 6.5 and 7.5; the culture pH is particularly preferably between 6.8 and 7.2.

[0086] The culture temperature is between 15 and 45° C. A temperature range of 18 to 40° C. is preferred, a temperature range of 25 to 35° C. is particularly preferred, and 30° C. is very particularly preferred.

[0087] In a preferred arrangement, the fermentation is a high cell density fermentation. A high cell density fermentation is understood to mean a fermentation during which the dry cell weight reaches more than 50 g / l. Particularly preferably, the dry cell weight is greater than 70 g / l.

[0088] Figure 1 Restriction and function diagram of plasmid pKD46 of Example 2 is shown.

[0089] Figure 2 Restriction and function maps of plasmid pAF-ts-pyrH generated in Example 2 are shown.

[0090] Figure 3 Restriction and function maps of plasmid pAF-ts-plsC generated in Example 2 are shown.

[0091] Figure 4Restriction and function diagram of plasmid pMT1 used in Example 5 is shown.

[0092] Figure 5 Restriction and function maps of the expression plasmid pcysEX-GAPDH-ORF306_tetR generated in Example 5 are shown.

[0093] Figure 6 Restriction and function maps of the expression plasmid pCGT_tetR generated in Example 6 are shown.

[0094] Figure 7 Restriction and function diagram of the expression plasmid pFab-anti-Lysozym_tetR generated in Example 7 is shown.

[0095] Figure 8 Restriction and function maps of the expression plasmid pcysEX-GAPDH-ORF306_pyrH1_tetR generated in Example 8 are shown.

[0096] Fig. 9 Restriction and function maps of the expression plasmid pCGT_pyrH1_tetR generated in Example 8 are shown.

[0097] Fig.10 Restriction and function maps of the expression plasmid pFab-anti-Lysozym_pyrH1_tetR generated in Example 8 are shown.

[0098] Fig.11 Restriction and function maps of the expression plasmid pcysEX-GAPDH-ORF306_plsC1_tetR generated in Example 8 are shown.

[0099] Fig.12 Restriction and function maps of the expression plasmid pCGT_plsC1_tetR generated in Example 8 are shown.

[0100] Fig.13 Restriction and function maps of the expression plasmid pFab-anti-Lysozym_plsC1_tetR generated in Example 8 are shown.

[0101] Fig.14 Restriction and function maps of the production plasmid pcysEX-GAPDH-ORF306_pyrH of the present invention generated in Example 9 are shown.

[0102] Fig.15 Restriction and function diagram of the production plasmid pCGT_pyrH of the present invention generated in Example 9 is shown.

[0103] Fig.16Restriction and function diagram of the production plasmid pFab-anti-Lysozym_pyrH of the present invention generated in Example 9 is shown.

[0104] Fig.17 Restriction and function maps of the production plasmid pcysEX-GAPDH-ORF306_plsC of the present invention generated in Example 9 are shown.

[0105] Fig.18 Restriction and function diagram of the production plasmid pCGT_plsC of the present invention generated in Example 9 is shown.

[0106] Fig.19 Restriction and function diagram of the production plasmid pFab-anti-Lysozym_plsC of the present invention generated in Example 9 is shown.

[0107] The following examples are used to further illustrate the present invention. All molecular biology and microbiology methods used, such as polymerase chain reaction (PCR), gene synthesis, DNA isolation and purification, restriction enzyme modified DNA, Klenow fragment and ligase, transformation, P1 transduction, etc., are performed in a manner known to those skilled in the art, described in the literature, or recommended by various manufacturers.

[0108] Example 1: Amplification of a marker gene (pyrH or plsC) with its own promoter

[0109] Primers pyrH-NcoI-fw (SEQ ID No. 5) and pyrH-NcoI-rev (SEQ ID No. 6) were used to amplify a DNA fragment of approximately 1.0 kb, encoding the pyrH gene including the native promoter region. The template used for the PCR reaction was chromosomal DNA from E. coli strain W3110 (ATCC 27325).

[0110] The 1.0 kb PCR fragment was purified by agarose gel electrophoresis and isolated from the agarose gel using the "QIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany) according to the information from the manufacturer. Afterwards, the purified PCR fragment was digested with the restriction enzyme NcoI and stored at -20°C. In a similar manner, a DNA fragment of approximately 1.0 kb in size encoding the plsC gene including the native promoter region was amplified, purified, digested and stored. For amplification, the primers plsC-NcoI-fw (SEQ ID No. 7) and plsC-NcoI-rev (SEQ ID No. 8) were used.

[0111] Example 2: Generation of plasmids pAF-ts-pyrH and pAF-ts-plsC using a temperature-sensitive replication origin

[0112] The starting plasmid for the construction of plasmids pAF-ts-pyrH and pAF-ts-plsC having a temperature-sensitive replication origin was plasmid pKD46 (Datsenko and Wanner, 2000, PNAS 97: 6640-6645). Figure 1 The restriction and function map of plasmid pKD46 is shown. The PCR product described in Example 1 and digested with NcoI (which PCR product encodes the pyrH gene or the plsC gene with its own promoter) was cloned into the NcoI restriction site of pKD46. The ligation preparation was transformed into "DH5α TM -T1R E. coli cells" (Life Technologies GmbH), amplified in these cells, and the DNA sequence of the isolated plasmids was verified by sequencing. Two of the four possible constructs generated in this way were named pAF-ts-pyrH and pAF-ts-plsC (see Figure 2 and 3 ).

[0113] Example 3: Transformation of selected E. coli strains using pAF-ts-pyrH or pAF-ts-plsC

[0114] Plasmids pAF-ts-pyrH and pAF-ts-plsC with temperature-sensitive replication origins described in Example 2 were transformed into two E. coli strains W3110 (ATCC 27325) and W3110lpp3 (described as "leaky" strains in US2008076158A1) using the CaCl2 method known to those skilled in the art. Transformed cells were selected on LB agar plates containing 100 mg / l ampicillin. The strains generated in this way were named W3110 / pAF-ts-pyrH, W3110lpp3 / pAF-ts-pyrH, W3110 / pAF-ts-plsC and W3110lpp3 / pAF-ts-plsC.

[0115] Example 4: Deletion of the pyrH gene (inactivation of uridylate kinase) or the plSC gene (inactivation of 1-acylglycerol-3-phosphate O-acyltransferase) in Escherichia coli

[0116] A) Deletion of the gene pyrH

[0117] According to the "λ Red method" developed by Datsenko and Wanner (Datsenko and Wanner, 2000, PNAS 97: 6640-6645), the gene pyrH encoding uridylate kinase (PyrH) in E. coli was deleted in E. coli strains W3110 / pAF-ts-pyrH and W3110lpp3 / pAF-ts-pyrH. The DNA fragment encoding the kanamycin resistance marker gene (kanR) was amplified using primers pyrH-fw (SEQ ID No. 9) and pyrH-rev (SEQ ID No. 10). Primer pyrH-fw encodes a sequence consisting of 30 nucleotides homologous to the 5'-end of the pyrH gene and a sequence comprising 20 nucleotides complementary to the DNA sequence encoding one of the two FRT sites (FLP recognition target sites) on plasmid pKD13 (ColiGenetic Stock Center (CGSC) No. 7633). Primer pyrH-rev encodes a sequence consisting of 30 nucleotides homologous to the 3'-end of the pyrH gene and a 20 nucleotide sequence complementary to the DNA sequence encoding the second FRT site on plasmid pKD13.

[0118] The amplified PCR products were introduced into E. coli strains W3110 / pAFts-pyrH and W3110lpp3 / pAF-ts-pyrH (see Example 3) by electroporation. Cells with a chromosomally integrated kanamycin resistance marker gene (kanR) were selected on LB agar plates containing 50 mg / l kanamycin and 100 mg / l ampicillin. Removal of the chromosomally introduced kanamycin resistance marker gene (kanR) was achieved using the enzyme FLP recombinase encoded on plasmid pCP20 (CGSC No.7629). Cells of pCP20 were selected on LB agar plates containing 100 mg / l ampicillin (pAF-ts-pyrH was selected) and 34 mg / l chloramphenicol (pCP20 was selected). Due to the temperature-sensitive origin of replication (ori), plasmid pCP20 was removed by culturing at a non-permissive, i.e. elevated temperature, such as 42°C after transformation.

[0119] The first selection for loss of the temperature-sensitive plasmid pCP20 and maintenance of the temperature-sensitive plasmid pAF-ts-pyrH was carried out on LB agar plates containing 100 mg / l ampicillin (selection of pAF-ts-pyrH). Afterwards, the preselected ampicillin-resistant bacterial clones were tested for kanamycin sensitivity, i.e., loss of the chromosomally introduced kanamycin marker gene, and chloramphenicol sensitivity, i.e., loss of the temperature-sensitive plasmid pCP20.

[0120] Using primers pyrH-check-for (SEQ ID No. 11) and pyrH-check-rev (SEQ ID No. 12), only kanamycin and chloramphenicol sensitive but ampicillin resistant clones were finally tested for chromosomal deletion of the pyrH gene. The template used for detection of chromosomal pyrH deletion by PCR was chromosomal DNA from selected ampicillin resistant, chloramphenicol and kanamycin sensitive clones.

[0121] The ampicillin-resistant E. coli strains thus generated and tested with chromosomal pyrH deletion and plasmid-encoded pyrH expression were designated W3110ΔpyrH / pAF-ts-pyrH and W3110lpp3ΔpyrH / pAF-ts-pyrH.

[0122] B) Deletion of the plsC gene

[0123] Similar to the pyrH gene, the gene plsC encoding 1-acylglycerol-3-phosphate O-acyltransferase (PlsC) in E. coli strains W3110 / pAF-ts-plsC and W3110lpp3 / pAF-ts-plsC (Datsenko and Wanner, 2000, PNAS 97: 6640-6645) was deleted. The DNA fragment encoding the kanamycin resistance marker gene (kanR) was amplified using primers plsC-fw (SEQ ID No. 13) and plsC-rev (SEQ ID No. 14). Primer plsC-fw encodes a sequence consisting of 30 nucleotides homologous to the 5' end of the plsC gene and a sequence comprising 20 nucleotides complementary to the DNA sequence encoding one of the two FRT sites (FLP recognition target sites) on plasmid pKD13 (ColiGenetic Stock Center (CGSC) No. 76333). Primer plsC-rev encodes a sequence consisting of 30 nucleotides homologous to the 3'-end of the plsC gene and a 20 nucleotide sequence complementary to the DNA sequence encoding the second FRT site on plasmid pKD13.

[0124] By electroporation, the PCR product of amplification is imported into Escherichia coli strain W3110 / pAFts-plsC and W3110lpp3 / pAF-ts-plsC (referring to Example 3). Enzyme FLP recombinase (encoding on plasmid pCP20) is used to remove the kanamycin resistance marker gene (kanR) of chromosome import again. The selection of the cell that contains pCP20 is also carried out on the LB agar plate containing 100mg / l penicillin (selecting pAF-ts-plsC) and 34mg / l chloramphenicol (selecting pCP20). On the LB agar plate containing 100mg / l penicillin (selecting pAF-ts-plsC), the selection for the first time of losing temperature-sensitive plasmid pCP20 and maintaining temperature-sensitive plasmid pAF-ts-plsC simultaneously is carried out. Afterwards, the preselected ampicillin-resistant bacterial clones were tested for kanamycin sensitivity, i.e., the loss of the chromosomally introduced kanamycin marker gene, and chloramphenicol sensitivity, i.e., the loss of the temperature-sensitive plasmid pCP20.

[0125] Finally, primers plsC-check-for (SEQ ID No. 15) and plsC-check-rev (SEQ ID No. 16) were used to detect chromosomal deletion of the plsC gene in these clones. The template used for detecting chromosomal plsC deletion by PCR was chromosomal DNA from selected ampicillin-resistant, chloramphenicol- and kanamycin-sensitive clones.

[0126] The ampicillin-resistant E. coli strains with chromosomal plsC deletion and plasmid-encoded plsC expression thus generated and tested were named W3110ΔplsC / pAF-ts-plsC and W3110lpp3ΔplsC / pAF-ts-plsC.

[0127] Example 5: Generation of a production plasmid containing an antibiotic resistance gene for the production of cysteine

[0128] The starting plasmids used for cloning and expression of the genes cysEX (encoding a feedback-resistant variant of serine acyltransferase; CysE) and orf306 (encoding O-acetylserine / cysteine ​​exporter; EamA) were the basic plasmid pMT1 and the production plasmid pACYC184-LH-cysEX-orf306 described in EP0885962B1.

[0129] pMT1 contains not only a tetracycline resistance gene (tetR), but also a tac promoter that is repressed by the product of the LacIq gene, which is also present on the plasmid and can be activated by inducers such as D-lactose or isopropyl-β-D-thiogalactopyranoside (IPTG).

[0130] Restriction and function map of plasmid pMT1 Figure 4 The sequence of plasmid pMT1 is stored in the sequence listing (SEQ ID No. 17).

[0131] To generate a new production plasmid for cysteine ​​production based on pMT1, the NcoI-BsaBI fragment from the plasmid pACYC184-LH-cysEX-orf306 (described in EP0885962B1) encoding the genes cysEX and orf306 was ligated with the 2458 bp NcoI-PvuII fragment from the plasmid pMT1 (encoding ColE1 ori and tetracycline resistance, tetR).

[0132] The ligation preparation was transformed into "DH5α TM -T1R E. coli cells" (Life Technologies GmbH), amplified in the cells, and the DNA sequence of the isolated plasmid was verified by sequencing. The resulting expression plasmid was named pcysEX-GAPDH-ORF306_tetR (see Figure 5 ).

[0133] Example 6: Generation of a production plasmid containing an antibiotic resistance gene for the production of α-CGTase

[0134] The starting plasmids used for cloning and expression of the cyclodextrin glycosyltransferase (CGTase) gene from Klebsiella pneumoniae M5a1 (Genbank nr No. M15264) were also plasmid pMT1 and plasmid pCGT described in US2008076158A1.

[0135] To generate a new production plasmid for producing CGTase based on pMT1, the MauBI-BsaI fragment from plasmid pCGT, encoding CGTase from Klebsiella pneumoniae M5a1, was ligated with the 4004 bp MauBI-BsaI fragment from plasmid pMT1. The 4004 bp fragment from plasmid pMT1 encodes ColE1 ori, lac / tac operator and tetracycline resistance gene (tetR).

[0136] The ligation preparation was transformed into "DH5α TM -T1R E. coli cells" (Life Technologies GmbH), amplified in the cells, and the DNA sequence of the isolated plasmid was verified by sequencing. The resulting expression plasmid was named pCGT_tetR (see Figure 6 ).

[0137] Example 7: Generation of a production plasmid containing antibiotic resistance genes for the production of Fab-resistant lysozyme

[0138] The starting plasmids used for cloning and expression of the gene for the anti-lysozyme Fab fragment were also the plasmids pMT1 and pFab-anti-lysozyme described in US20080076158A1.

[0139] In order to generate a new production plasmid for the production of the antibody fragment Fab-anti-lysozyme based on pMT1, the heavy chain (V H -C H 1 domain) and light chain (V L -C L The Fab-resistant MauBI-BsaI fragment of plasmid pMT1 (containing the Fab domain) was ligated with a 4004 bp MauBI-BsaI fragment from plasmid pMT1 encoding ColE1 ori, lac / tac operator and tetracycline resistance gene (tetR).

[0140] The ligation preparation was transformed into "DH5α TM -T1R E. coli cells" (Life Technologies GmbH), amplified in the cells, and the DNA sequence of the isolated plasmid was verified by sequencing. The resulting expression plasmid was named pFab-anti-Lysozym_tetR (see Figure 7 ).

[0141] Example 8: Generation of production plasmids containing the marker gene pyrH or plsC as a basis for the production plasmids of the present invention without antibiotic resistance genes

[0142] The starting plasmids used to generate production plasmids containing pyrH or plsC as marker genes are plasmids pcysEX-GAPDH-ORF306_tetR, pCGT_tetR and pFab-anti-Lysozym_tetR as described in Examples 5-7. All of these plasmids have a single NcoI restriction site (see Figures 5-7). This universal NcoI restriction site is used for cloning or integration of the gene pyrH or plsC.

[0143] To this end, the PCR product described in Example 1 and cut with the restriction enzyme NcoI was ligated with the plasmids pcysEX-GAPDH-ORF306_tetR, pCGT_tetR and pFab-anti-Lysozyme_tetR, which had also been cut with NcoI. The respective ligation preparations were transformed into "DH5α TM-T1R E. coli cells" (Life Technologies GmbH), amplified in said cells and the DNA sequence of the isolated plasmids verified by sequencing. Depending on the orientation and the marker gene used, the resulting constructs were named as follows:

[0144] pcysEX-GAPDH-ORF306_pyrH1_tetR (see Figure 8 ) and pcysEX-GAPDH-ORF306_pyrH2_tetR

[0145] pCGT_pyrH1_tetR (see Fig. 9 ) and pCGT_pyrH2_tetR

[0146] pFab-anti-Lysozyme_pyrH1_tetR (see Fig.10 ) and pFab-anti-Lysozyme_pyrH2_tetR

[0147] pcysEX-GAPDH-ORF306_plsC1_tetR (see Fig.11 ) and pcysEX-GAPDH-ORF306_plsC2_tetR

[0148] pCGT_plsC1_tetR (see Fig.12 ) and pCGT_plsC2_tetR

[0149] ·pFab-anti-Lysozyme_plsC1_tetR (see Fig.13 ) and pFab-anti-Lysozyme_plsC2_tetR

[0150] To finally remove the tetR gene, the procedure was continued using the variants pcysEX-GAPDH-ORF306_pyrH1_tetR, pCGT_pyrH1_tetR, pFab-anti-Lysozyme_pyrH1_tetR, pcysEX-GAPDH-ORF306_plsC1_tetR, pCGT_plsC1_tetR and pFab-anti-Lysozyme_plsC1_tetR (see Figure 8-13 ).

[0151] Example 9: Removal of the antibiotic resistance gene tetR and transformation of a production plasmid containing pyrH or plsC as a remaining marker gene into an E. coli strain with a chromosomal pyrH or plsC deletion

[0152] The starting plasmids used to generate production plasmids without the antibiotic resistance gene tetR and containing pyrH or plsC as marker genes were the plasmids pcysEX-GAPDH-ORF306_pyrH1_tetR, pCGT_pyrH1_tetR, pFab-anti-Lysozyme_pyrH1_tetR, pcysEX-GAPDH-ORF306_plsC1_tetR, pCGT_plsC1_tetR and pFab-anti-Lysozyme_plsC1_tetR as described in Example 8. The antibiotic resistance gene tetR was removed from the plasmids pFab-anti-Lysozyme_pyrH1_tetR and pFab-anti-Lysozym_plsC1_tetR as described in Example 8 by digestion with the restriction enzyme ClaI and subsequent religation.

[0153] For the plasmids pcysEX-GAPDH-ORF306_pyrH1_tetR and pcysEX-GAPDH-ORF306_plsC1_tetR, a similar procedure was performed, with the difference that the gene tetR was removed by partial digestion with ClaI, since two further ClaI restriction sites are located in the structural genes cysEX and orf306 (see Figure 8 and 11 ).

[0154] In the case of pCGT_plsC1_tetR, the tetR gene was removed from the plasmid by digestion with the enzymes StuI (cuts to leave blunt ends) and FspI (cuts to leave blunt ends).

[0155] In the case of pCGT_pyrH1_tetR, the tetR gene was likewise removed by partial digestion with the enzymes StuI (cuts to leave blunt ends) and FspI (cuts to leave blunt ends), since a further FspI restriction site is located within the pyrH gene (see Fig. 9 ).

[0156] After restriction digestion, the respective linear vector fragment without tetR was purified by agarose gel electrophoresis and isolated from the agarose gel using the "QIAquick Gel Extraction Kit" (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. Afterwards, the tetR-free vector fragment was religated.

[0157] Using the modified CaCl method, the corresponding ligation preparations were transformed into the strains W3110ΔpyrH / pAF-ts-pyrH and W31101pp3ΔpyrH / pAF-ts-pyrH or W3110ΔpyrH / pAF-ts-plsC and W31101pp3ΔpyrH / pAF-ts-plsC described in Example 4. For the transformation, the antibiotic-free production plasmid containing pyrH or plsC as marker gene was introduced into the E. coli strain with the corresponding chromosomal deletion (pyrH or plsC) and the following procedure was performed:

[0158] After adding 5-20 μl of the ligation preparation to 100 μl of CaCl competent cells of strains W3110 pyrH / pAF-ts-pyrH and W31101pp3 pyrH / pAF-ts-pyrH or W3110plsC / pAF-ts-plsC and W31101pp3 plsC / pAF-ts-plsC, the cells were incubated on ice for another 30 minutes. After a brief heat shock of 45 seconds at 42°C, the cells were cooled on ice for 2 minutes. Afterwards, 900 μl of LB medium was added to the transformation preparation, and the cells were incubated / regenerated at 47°C-55°C for 30-90 minutes instead of at 37°C as usual. Then further incubated at 40-45°C for 15-24 hours at an elevated non-permissive temperature on LB agar plates or in liquid LB medium without antibiotics (e.g., without tetracycline).

[0159] A 30-90 minute regeneration phase at 47-55°C and 15 to 24 hours of incubation at elevated nonpermissive temperature facilitates the exchange of the temperature sensitive plasmid pAF-ts-pyrH or pAF-ts-plsC into the final antibiotic-free production plasmid containing pyrH or plsC as the new selectable marker gene.

[0160] Optimal transformation results were achieved when transformed cells were regenerated at 52°C for 60 minutes and then incubated on LB agar plates at 42°C for 20 hours.

[0161] First, the loss of the temperature-sensitive plasmid pAF-ts-pyrH or pAF-ts-plsC and the simultaneous replacement with the respective production plasmid containing pyrH or plsC without the tetracycline resistance gene tetR were preliminarily selected on LB agar plates without antibiotics.

[0162] Afterwards, the pre-selected bacterial clones were tested for ampicillin sensitivity, i.e., loss of the temperature-sensitive plasmid pAF-ts-pyrH or pAF-ts-plsC

[0163] The production plasmids encoding pyrH or plsC from the ampicillin-sensitive clones were finally tested by restriction digestion. Restriction maps of the production plasmids encoding pyrH, pcysEX-GAPDH-ORF306_pyrH, pCGT_pyrH, and pFab-anti-Lysozyme_pyrH, each lacking the antibiotic resistance gene tetR, are shown in Figure 14-16 Restriction maps of the production plasmids pcysEX-GAPDH-ORF306_plsC, pCGT_plsC, and pFab-anti-Lysozyme_plsC, each lacking the antibiotic resistance gene tetR, encoding plsC, are shown in Figure 17-19 .

[0164] The antibiotic-resistant E. coli strains thus generated and tested containing a production plasmid encoding pyrH or plsC and having a chromosomal pyrH or plsC deletion have the following designations:

[0165] ·W3110ΔpyrH / pcysEX-GAPDH-ORF306_pyrH

[0166] ·W31101pp3ΔpyrH / pCGT_pyrH

[0167] ·W3110lpp3ΔpyrH / pFab-anti-Lysozym_pyrH

[0168] ·W3110ΔplsC / pcysEX-GAPDH-ORF306_plsC

[0169] ·W3110lpp3ΔplsC / pCGT_plsC

[0170] ·W3110lpp3ΔplsC / pFab-anti-Lysozym_plsC

[0171] Example 10: Cysteine ​​fermentation

[0172] Pre-culture 1:

[0173] In an Erlenmeyer bottle (100 ml), 20 ml of LB medium were inoculated with the specific E. coli strains W3110 / pcysEX-GAPDH-ORF306_tetR, W3110ΔpyrH / pcysEX-GAPDH-ORF306_pyrH or W3110ΔplsC / pcysEX-GAPDH-ORF306_plsC and incubated for 7 hours on a shaker (150 rpm, 30° C.). For the cultivation of the prior art construct W3110 / pcysEX-GAPDH-ORF306_tetR, i.e. with antibiotics as selection agent, the medium was supplemented with 15 mg / L tetracycline.

[0174] Pre-culture 2:

[0175] After that, the entire preculture 1 was transferred to 100 ml of SM1 medium (12 g / l K2HPO4, 3 g / l KH2PO4, 5 g / l (NH4)2SO4, 0.3 g / l MgSO4×7H2O, 0.015 g / l CaCl2×2H2O, 0.002 g / l FeSO4×7H2O, 1 g / l sodium citrate×2H2O, 0.1 g / l NaCl, 1 ml / l trace element solution containing 0.15 g / l Na2MoO4×2H2O, 2.5 g / l H3BO3, 0.7 g / l CoCl2 x 6H2O, 0.25 g / l CuSO4×5H2O, 1.6 g / l MnCl2×4H2O, 0.3 g / l ZnSO4×7H2O, supplemented with 5 g / l Glucose and 5 mg / l vitamin B1. The culture was shaken at 150 rpm for 17 hours at 30°C in an Erlenmeyer bottle (1 L). After this incubation, the optical density at 600 nm (OD600) was between 3 and 5. For the cultivation of W3110 / pcysEX-GAPDH-ORF306_tetR of the prior art, antibiotics were used as selection agents and the culture medium was supplemented with 15 mg / L tetracycline.

[0176] Main culture:

[0177] Fermentation was carried out in a BIOSTAT B fermenter from Sartorius Stedim. A culture vessel with a total volume of 2 L was used. The fermentation medium (900 ml) contained 15 g / l glucose, 10 g / l tryptone (Difco), 5 g / l yeast extract (Difco), 5 g / l (NH4)2SO4, 1.5 g / l KH2PO4, 0.5 g / l NaCl, 0.3 g / l MgSO4×7H2O, 0.015 g / l CaCl2×2H2O, 0.075 g / l FeSO4×7H2O, 1 g / l sodium citrate×2H2O and 1 ml trace element solution (see above) and 0.005 g / l vitamin B1. The pH in the fermenter was initially adjusted to 6.5 by pumping in a 25% NH4OH solution. During the fermentation, the pH was automatically corrected to a level of 6.5 using 25% NH4OH to maintain the pH. For inoculation, 100 ml of preculture 2 were pumped into the fermenter vessel. The starting amount was therefore approximately 1 L. The culture was initially stirred at 400 rpm and aerated with 2 vvm of compressed air sterilized by passing through a sterile filter. Under these starting conditions, the oxygen probe was calibrated to 100% saturation before inoculation. The nominal value for oxygen saturation during the fermentation was set at 50%. After the O2 saturation fell below the nominal value, a regulation cascade was started to bring the O2 saturation back to the nominal value. In this regard, the gas supply was first increased continuously (maximum 5 vvm) and then the stirring rate was increased continuously (maximum 1500 rpm).

[0178] The fermentation was carried out at a temperature of 30° C. After a fermentation time of 2 hours, a sulphur source was added at a rate of 1.5 ml / hour in the form of a sterile 60% sodium thiosulfate×5H2O stock solution. Once the initial glucose content of 15 g / l in the fermenter had fallen to approximately 2 g / l, a 56% glucose solution was metered in continuously. The feed rate was set so that the glucose concentration in the fermenter no longer exceeded 2 g / l from then on.

[0179] Glucose was determined using a glucose analyzer from YSI (Yellow Springs, Ohio, USA).For fermentation of the prior art construct W3110 / pcysEX-GAPDH-ORF306_tetR, ie with antibiotics as selection agent, the medium was supplemented with 15 mg / L tetracycline.

[0180] The fermentation time was 48 hours. Thereafter, samples were collected and the contents of L-cysteine ​​and its derivatives in the culture supernatant and the precipitate were determined, respectively, especially L-cysteine ​​and tetrahydrothiazole in the supernatant and L-cystine in the precipitate. For this purpose, the colorimetric assay of Gaitonde (Gaitonde, MK (1967), Biochem. J. 104, 627–633) was used in each case. The L-cystine present in the precipitate must first be dissolved in 8% hydrochloric acid before it can be quantified in the same manner. The total amount of cysteine ​​listed in Table 1 is equivalent to the sum of L-cysteine ​​in the culture supernatant and L-cystine in the precipitate. In this regard, each L-cystine molecule corresponds to two L-cysteine ​​molecules.

[0181] Table 1: Total cysteine ​​(L-cysteine) in the culture medium after 48 hours 培养物上清 +L-Cystine 沉淀 ) content and the stability of the production plasmid

[0182]

[0183] *Constructs in the context of prior art (comparative example)

[0184] **Constructs of the present invention

[0185] Example 11: Secretory production of cyclodextrin glycosyltransferase at 10 L scale (fermentation)

[0186] With the help of lpp mutants of Escherichia coli, biotechnologically relevant enzymes such as CGTases can be produced and secreted into the culture medium (US2008076158A1).

[0187] Secretory production of CGTase was performed in a 10 L stirred fermenter using strains W31101pp3 / pCGT_tetR (control), W31101pp3ΔpyrH / pCGT_pyrH and W31101pp3ΔpyrH / pCGT_plsC.

[0188] 1:10 ratio was added to 6 l of fermentation medium FM4 (1.5 g / l KH2PO4, 5 g / l (NH4)2SO4, 0.5 g / l MgSO4×7H2O, 0.15 g / l CaCl2×2H2O, 0.075 g / l FeSO4×7H2O, 1 g / l sodium citrate×2H2O, 0.5 g / l NaCl, 1 ml / l trace element solution (0.15 g / l Na2MoO4×2H2O, 2.5 g / l Na3BO3, 0.7 g / l CoCl2×6H2O, 0.25 g / l CuSO4×5H2O, 1.6 g / l MnCl2×4H2O, 0.3 g / l ZnSO4×7H2O), 5mg / l vitamin B1, 3g / l Phytone, 1.5g / l yeast extract, 10g / l glucose) inoculated with a preculture grown overnight in the same medium. During the fermentation, the temperature was set at 30°C and the pH was kept constant at 7.0 by metering NH4OH or H3PO4. Glucose was metered throughout the fermentation process, striving for a maximum glucose concentration of <10g / l in the fermentation medium. Expression was induced by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to 0.1mM at the end of the logarithmic growth phase.

[0189] For the fermentation of the prior art construct W31101pp3 / pCGT_tetR, antibiotics were used as selection agents and the culture medium was supplemented with 15 mg / L tetracycline.

[0190] After 72 hours of fermentation, samples were collected, cells were removed from the fermentation medium by centrifugation, and the CGTase content in the fermentation supernatant was determined as described in Example 4 of US2008076158A1. Table 2 lists the yield and activity of functional CGTase in the fermentation supernatant.

[0191] Table 2: Cyclodextrin glycosyltransferase production in the fermentation supernatant after 72 hours of fermentation

[0192]

[0193] *Constructs in the context of the prior art (comparative examples)

[0194] **Constructs of the present invention

[0195] Example 12: Production of Fab antibody fragments against lysozyme by secretory fermentation at 10 L scale

[0196] Functional Fab antibody fragments can also be produced extracellularly with the help of the lpp mutant of E. coli (US2008076158A1). In this case, the cell must simultaneously synthesize the corresponding fragment of the light chain containing the domains VL and CL and the corresponding fragment of the heavy chain containing the domains VH and CH1, which are then secreted into the periplasm and finally secreted into the fermentation medium. Outside the cytoplasm, the two chains assemble to form a functional Fab fragment.

[0197] This example describes the generation of a Fab fragment of the well-characterized anti-lysozyme antibody D1.3.

[0198] Plasmids pFab-anti-Lysozym_tetR, pFab-anti-Lysozym_pyrH and pFab-anti-Lysozym_plsC contain not only the marker genes tetR, pyrH and plsC, respectively, but also the structural genes of the HC and LC of the Fab fragments in the form of an operon. In this case, HC is in frame with the ompA signal sequence (ompA SS ) is fused to the 3' end of the CGTase signal sequence (cgt SS ) is fused to the 3' end of ompA SS -HC-cgt SS The expression of the -LC operon is under the control of the tac promoter.

[0199] Based on CGTase, the production of anti-lysozyme Fab fragments was carried out similarly to the method described in Example 11, using strains W3110lpp3 / pFab-anti-Lysozym_tetR, W3110lpp3ΔpyrH / pFab-anti-Lysozym_pyrH and W3110lpp3ΔplsC / pFab-anti-Lysozym_plsC. For the fermentation of E. coli W3110lpp3 / pFab-anti-Lysozym_tetR in the prior art, i.e., using antibiotics as selection agents, the culture medium was supplemented with 15 mg / L tetracycline.

[0200] After 72 hours of fermentation, samples were collected and the cells were removed from the fermentation medium by centrifugation.

[0201] The anti-lysozyme Fab fragments were purified from the fermentation supernatant by affinity chromatography as described by Skerra (1994, Gene 141, 79-84).

[0202] The purified anti-lysozyme Fab fragments were quantified and their activity was determined by ELISA assay using lysozyme as antigen (Skerra, 1994, Gene 141, 79-84).

[0203] Table 2 lists the projected yields of functional anti-lysozyme Fab fragments in the fermentation supernatants, based on the isolation of 20 ml of fermentation supernatant after 72 h of fermentation in each case.

[0204] Table 3: Yield of anti-lysozyme Fab fragments in the fermentation supernatant after 72 hours of fermentation.

[0205]

[0206]

[0207] *Constructs in the context of prior art (comparative example)

[0208] **Constructs of the present invention

[0209] Example 13: Determination of plasmid stability

[0210] Plasmid stability is tested by plasmid preparation and subsequent restriction digestion. For this purpose, cultivation of the production strain is completed (e.g. after 72 hours of fermentation) and various dilutions of the culture are subsequently plated on LB agar plates. In order to subsequently determine plasmid stability, i.e. identify cells (colonies) carrying the plasmid, only LB plates with individual colonies are used for evaluation.

[0211] A total of 50 individual colonies were cultured in liquid LB medium for 15-20 hours, and then plasmid DNA was isolated from the cultures. The characteristic restriction pattern of the individual production plasmids was used as the basis for verifying the correctness of the isolated plasmids.

Claims

1. A microbial strain for producing low molecular weight substances or proteins, the genome of which contains a mutation in a gene, which causes auxotrophy in the strain, the strain also containing a production plasmid encoding at least one enzyme or at least one recombinant protein and a functional copy of the gene, the enzyme is used to produce low molecular weight substances, the chromosomal inactivation of the gene causes auxotrophy, characterized in that the auxotrophy is an irreparable auxotrophy, and the gene is the plsC gene or a homologous gene thereof; wherein the microorganism is Escherichia coli, the sequence of the plsC gene is SEQ ID NO: 3, and the homologous gene encodes a protein identical to the protein encoded by the plsC gene and has a sequence identity of greater than 70% with the sequence of the plsC gene; and The non-complementable nutritional deficiency refers to the nutritional deficiency that reduces the growth of microbial cells or causes the death of microbial cells and cannot be supplemented by adding metabolic specific precursors, intermediates and / or end products to the growth medium.

2. The microbial strain according to claim 1, characterized in that a gene mutation causing an irreparable auxotrophic deficiency in the strain results in the inactivation of said gene.

3. The microbial strain according to claim 1 or 2, characterized in that the gene mutation causing the irreparable auxotrophic deficiency in the strain results in the inactivation of the activity of the gene product encoded by the gene.

4. A method for producing a microbial strain according to any one of claims 1 to 3, characterized in that a temperature-sensitive plasmid is introduced into a microbial strain, the strain having a gene that can be converted into a gene causing an auxotrophic deficiency that cannot be complemented in the strain by mutation or deletion, the temperature-sensitive plasmid having a functional copy of the gene to be mutated or deleted, then the genome of the strain is mutated, whereby the strain has a mutation in the gene that causes an auxotrophic deficiency that cannot be complemented in the strain, and a functional copy of the gene is present on the temperature-sensitive plasmid, then the temperature-sensitive plasmid is exchanged with a production plasmid in the strain at a non-permissive temperature, wherein the production plasmid contains a gene encoding an enzyme or a recombinant protein for producing a low molecular weight substance, and a functional copy of a gene causing auxotrophy, wherein the gene is the plsC gene or a homologous gene thereof; wherein the microorganism is Escherichia coli, the sequence of the plsC gene is SEQ ID NO: 3, and the homologous gene encodes a protein identical to the protein encoded by the plsC gene and has a sequence identity of greater than 70% with the sequence of the plsC gene; and The non-complementable nutritional deficiency refers to the nutritional deficiency that reduces the growth of microbial cells or causes the death of microbial cells and cannot be supplemented by adding metabolic specific precursors, intermediates and / or end products to the growth medium.

5. The method according to claim 4, Features The temperature-sensitive plasmid has a temperature-sensitive replication origin.

6. The method according to claim 5, characterized in that the cells are exposed to a temperature shock of 47-55°C for 30-90 minutes immediately after transformation with the production plasmid and subsequently further incubated at a non-permissive temperature of 37-45°C.

7. A method for producing low molecular weight substances or proteins using a microbial strain in a fermentation medium, the method being characterized in that the microbial strain according to any one of claims 1 to 3 and an antibiotic-free fermentation medium are used.